Evaluating Artificial Intelligence-Based Clinical Decision Support for Sepsis and ARDS
Launched by UNIVERSITY OF PENNSYLVANIA · Jun 9, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This study is looking at how well an artificial intelligence (AI) tool can help doctors make treatment decisions for patients with sepsis and acute respiratory distress syndrome (ARDS), two serious conditions often seen in intensive care units. The AI system offers treatment suggestions, and the study wants to see if these suggestions are as safe and appropriate as those made by real doctors. Participants in the study will be critical care doctors and advanced practice providers who will review patient cases and treatment plans, then decide if the recommendations seem safe and whether they believe the advice came from a human or the AI.
To take part, you must be a licensed doctor (MD or DO) or an advanced practice provider like a nurse practitioner or physician assistant, working in critical care or emergency medicine at a hospital. You should have completed your residency training. Participants will complete an online survey where they review several patient stories and treatment plans, then give their opinions on the safety and source of the recommendations. This study is not yet recruiting, but it aims to help improve how AI tools might assist doctors in caring for very sick patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Working as a physician (i.e., MD, DO) or an advanced practice provider (i.e., nurse practitioner, physician assistant)
- • Working at a hospital or medical center in medical critical care, anesthesia critical care, surgical critical care, or emergency medicine
- Exclusion Criteria:
- • Has not completed a residency training program (i.e., medical intern or resident)
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Gary Weissman, MD, MSHP
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported